Contract Deobligations Alert — February 24, 2026

$209M obligated across MAPP and Medicines Company for long-term viral/infectious disease programs, with 25-45% already outlayed and options to $299M+.

$94M firm-fixed-price order to veteran-owned firm highlights competitive edge in disability exams, despite 11% outlay on ended period.

$175M obligation with $0 outlay on 2020-ended CMS delivery order indicates potential deobligation without execution.

Low outlays vs obligations: $0 on QLARANT $175M, 11% on Veterans $94M, 48% on Medicines $98M; signals potential deobligation-driven funding shortfalls.

Expired performance periods without extensions on three contracts (QLARANT 2020, Veterans 2020), amplifying deobligation risks.

Dependence on HHS BARDA continuity for unexercised options ($299M MAPP potential vs $111M obligated).

BARDA options exercise and extensions to 2036 could unlock $188M+ additional value in biotech R&D.

Veteran-owned edge in VA contracting for $94M+ medical evals, with remaining $84M outlay potential.

Follow-on data processing awards post-$175M CMS deobligation, leveraging prior full/open competition win.

80% of value ($384M/478M) in HHS contracts, with 67% bullish biotech R&D for antivirals/anti-infectives amid deobligations.

Three of four contracts pre-2023 with outlays <50% of obligations, concentrated in health IT/services.

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$111M BARDA obligation with $54M outlayed and $188M options; highest growth potential.", "trigger"=>"Option exercises or 2031+ extensions"}

{"entity"=>"HHS BARDA Funding", "reason"=>"Two contracts total $209M, 44% of stream value; signals health security trends.", "trigger"=>"New viral R&D awards >$100M"}

{"entity"=>"QLARANT Integrity Solutions", "reason"=>"$175M with $0 outlay signals deobligation completion; test for follow-ons.", "trigger"=>"New CMS data processing RFP wins"}